DETECTION OF ALZHEIMER'S DISEASE USING A POLYMER NANOWIRE-BASED BIOSENSOR

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$367,279.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43AG029006-01A1
Award Id:
88661
Agency Tracking Number:
AG029006
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
INNOSENSE, LLC, 2531 W 237TH ST, STE 127, TORRANCE, CA, 90505
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
114060861
Principal Investigator:
() -
Business Contact:
() -
kisholoy.goswami@innosense.us
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): InnoSense LLC (ISL) submits this revised application with the intent of developing a cost-effective and highly sensitive polymer nanowire-based electronic biosensor (PNEBD) for the early screening of Alzheimer's disease (AD). This device is expected to have potentially significant implications in the early treatment and possible delay of debilitating symptoms associated with this disease. The Phase I project is focused on the development and verification of a high-throug hput device based on silicon photolithography processes and template-free electrodeposition of functionalized conductive polymers between narrow-gap electrode junctions. Six tasks have been proposed to establish the Phase I feasibility of detecting amyloid -a derived diffusible ligand (ADDL) antigen, a biomarker for AD, using amyloid-a (Aa) oligomer specific antibody to ADDLs. Current evidence strongly suggests a central role for amyloid-a (Aa) in the pathogenesis of AD. At the present time there is no defin ite clinical diagnosis for AD other than autopsy. It has been demonstrated that ADDLs are present at significantly elevated levels in the autopsied brain samples of humans with AD. This association of ADDLs with AD suggests that the PNEBD device could prov ide a definitive molecular basis for the laboratory diagnosis of AD. For ensuring success, a highly skilled research team, including an expert on AD, has been assembled to execute the project. Development of ultrasensitive detection methods for early scree ning of Alzheimer's disease (AD) is an important issue in clinical disease diagnosis and mechanistic understanding of Alzheimer's disease (AD). AD is a progressive neurodegenerative disease for which there is neither a cure nor an early diagnostic device. It is the leading cause of dementia in people over age 65 affecting over four million Americans. Despite its utmost importance, no ultrasensitive technologies have been developed for clinical lab diagnostic of AD. InnoSense LLC aims to fill this void by de veloping a cost-effective and highly-sensitive polymer nanowire-based electronic biosensor device (PNEBD). This device will utilize electrochemically grown polymer nanowires at micro- to nanoscale patterned electrode junctions for detecting amyloid-a deriv ed diffusible ligands (ADDLs). ADDL has been established as a biomarker for AD. The purpose of using an electrochemical method is to grow template-free, low-cost and high quality polymer nanowires on to the electrode junctions. This direct, one-step fabric ation technique is scalable. This project will advance our knowledge on the detection of Alzheimer's disease.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government